Recent studies have shown that mTOR inhibition can increase CD133+ subsets by abrogating differentiation of CD133+ cells and enhancing apoptosis of CD133− subpopulations in liver cancer cell lines [40]. This evidence concerns the gene MTOR and liver cancer.